Leukaemia Trial, Recruiting (NCT06814444)

Leukaemia Trial, Recruiting NCT06814444 Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT06814444 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For patients:

You have been diagnosed with Acute Leukaemia
You are eligible to receive a treatment plan that includes conventional chemotherapy or newer types of therapies, such as treatments that target specific parts of cancer cells or treatments that work with the immune system
You are 18 years old or older
You are willing and able to sign a consent form at the time of your diagnosis

For healthy volunteers (volunteers with AIL Bologna ODV):

You are 18 years old or older
You are willing and able to sign a consent form

Who may not be able to join:

There are no stated exclusion criteria for this trial — meaning no specific reasons have been listed that would prevent someone from participating (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 5 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Antonio Curti, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phone: +39 0512144074

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06814444

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase: Not Applicable

Status: Recruiting

Condition: Leukaemia

Trial contact: +39 0512144074

More information: https://clinicaltrials.gov/study/NCT06814444

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For patients:

You have been diagnosed with Acute Leukaemia
You are eligible to receive a treatment plan that includes conventional chemotherapy or newer types of therapies, such as treatments that target specific parts of cancer cells or treatments that work with the immune system
You are 18 years old or older
You are willing and able to sign a consent form at the time of your diagnosis

For healthy volunteers (volunteers with AIL Bologna ODV):

You are 18 years old or older
You are willing and able to sign a consent form

Who may not be able to join:

There are no stated exclusion criteria for this trial — meaning no specific reasons have been listed that would prevent someone from participating (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 5 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Registry

ClinicalTrials.gov

Start date

11 November 2023

Est. completion

11 December 2029

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

the association between the molecular and metabolic characteristics of leukaemic cells and those of the surrounding immune system, in order to identify immuno-modulatory metabolic mechanisms implemented by malignant cells; the association between immunometabolic signatures and response to therapies; the role of EVs as a vehicle for metabolic units capable of regulating the metabolism of immune system cells

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov